- Home
- CRVS vs LAAC Comparison
CRVS vs LAAC Comparison
Compare CRVS & LAAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- LAAC
- Stock Information
- Founded
- CRVS 2014
- LAAC 2007
- Country
- CRVS United States
- LAAC Canada
- Employees
- CRVS N/A
- LAAC N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- LAAC
- Sector
- CRVS Health Care
- LAAC
- Exchange
- CRVS Nasdaq
- LAAC Nasdaq
- Market Cap
- CRVS 516.0M
- LAAC 490.6M
- IPO Year
- CRVS 2016
- LAAC N/A
- Fundamental
- Price
- CRVS $5.22
- LAAC $2.87
- Analyst Decision
- CRVS Strong Buy
- LAAC Buy
- Analyst Count
- CRVS 5
- LAAC 2
- Target Price
- CRVS $12.38
- LAAC $5.13
- AVG Volume (30 Days)
- CRVS 1.6M
- LAAC 1.1M
- Earning Date
- CRVS 11-12-2024
- LAAC 11-05-2024
- Dividend Yield
- CRVS N/A
- LAAC N/A
- EPS Growth
- CRVS N/A
- LAAC 3133.17
- EPS
- CRVS N/A
- LAAC 7.78
- Revenue
- CRVS N/A
- LAAC N/A
- Revenue This Year
- CRVS N/A
- LAAC N/A
- Revenue Next Year
- CRVS N/A
- LAAC $201.44
- P/E Ratio
- CRVS N/A
- LAAC $0.37
- Revenue Growth
- CRVS N/A
- LAAC N/A
- 52 Week Low
- CRVS $1.30
- LAAC $2.07
- 52 Week High
- CRVS $10.00
- LAAC $5.79
- Technical
- Relative Strength Index (RSI)
- CRVS 41.23
- LAAC 45.65
- Support Level
- CRVS $4.60
- LAAC $2.78
- Resistance Level
- CRVS $6.47
- LAAC $3.08
- Average True Range (ATR)
- CRVS 0.39
- LAAC 0.14
- MACD
- CRVS 0.06
- LAAC 0.02
- Stochastic Oscillator
- CRVS 33.16
- LAAC 45.08
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About LAAC Lithium Americas (Argentina) Corp.
Lithium Argentina is a pure-play lithium producer. The company owns two neighboring lithium brine resources in northwest Argentina: Cauchari-Olaroz and Pastos Grandes. Cauchari-Olaroz entered production in 2023, while Pastos Grandes is still in development. Lithium Argentina plans for both resources to be fully integrated with onside downstream processing capabilities and will sell into the lithium chemical market.